title: REACH: international prospective observational registry in patients at risk of atherothrombotic events. Results for the French arm at baseline and one year.
abstract: BACKGROUND
  Atherothrombosis is a systemic, diffuse disease associated with a high risk of cardiovascular morbidity and mortality. It is the main cause of death in Western populations, a major public health concern and its prevalence will further increase in the future.
  
  
  OBJECTIVE
  To evaluate the rate of major vascular events at 1 year in French patients with confirmed atherothrombotic disease, recruited in the REACH international registry.
  
  
  METHODS
  The REACH Registry has recruited 55.000 patients in 44 countries, aged at least 45 years and suffering from established atherothrombotic disease (EAD). In France, 713 investigators selected 3.514 patients with EAD between December 2003 and June 2004. Each investigator had to include 5 to 10 patients presenting after a first documented event of cerebrovascular disease (CVD), coronary artery disease (CAD) or lower limb peripheral arterial occlusive disease (PAD). The patients were followed up for 1 year with collection of major vascular events.
  
  
  RESULTS
  Among the 3514 French patients with EAD in the REACH registry, 2.373 (68%) had documented coronary disease, 778 (22%) had an ischemic stroke and 923 (26%) had documented PAD. One quarter of CAD patients, one third of CVD patients and one half of PAD patients had another atherothrombotic disease localization. Follow-up at 1 year was documented for 3.373 patients with EAD. The 1-year event rate in patients who had EAD was a function of the number of atherothrombotic localizations: the vascular death rate was 1.8% if there was a single localization and 4.1% if there were 2 or 3 localizations, and the composite death, infarct and stroke rates were 3.8% and 7.2% respectively and 11.7% and 22.3% respectively if hospitalizations were added to the latter endpoint.
  
  
  CONCLUSIONS
  The number of major vascular events during the first year is high in EAD patients although these patients were followed up on an outpatient basis and are considered to be stable. In patients with prior EAD, there was a close link between the incidence of major vascular events and the number of symptomatic arterial beds (2 or 3 sites). The risk of a major vascular event was twice as high in patients with polyvascular involvement than in those who only had one affected artery.
authors.affiliation: Service de cardiologie, Groupe hospitalier Pitié-Salpêtrière, Paris.
authors.forename: P
authors.initials: P
authors.lastname: Sabouret
authors.forename: P
authors.initials: P
authors.lastname: Cacoub
authors.forename: J
authors.initials: J
authors.lastname: Dallongeville
authors.forename: M
authors.initials: M
authors.lastname: Krempf
authors.forename: J L
authors.initials: JL
authors.lastname: Mas
authors.forename: J F
authors.initials: JF
authors.lastname: Pinel
authors.forename: P
authors.initials: P
authors.lastname: Priollet
authors.forename: G
authors.initials: G
authors.lastname: Steg
authors.forename: D
authors.initials: D
authors.lastname: Taminau
authors.forename: G
authors.initials: G
authors.lastname: Montalescot
mesh_terms: D000368:Aged; D050197:Atherosclerosis / Q000150:complications* / Q000188:drug therapy; D002561:Cerebrovascular Disorders / Q000453:epidemiology* / Q000209:etiology; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000209:etiology; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000453:epidemiology* / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011446:Prospective Studies; D012042:Registries; D020521:Stroke / Q000453:epidemiology; D013927:Thrombosis / Q000150:complications* / Q000188:drug therapy
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010975:Platelet Aggregation Inhibitors